Ethiopia vs Jordan: Average cost of multi drug-resistant tuberculosis treatment
Ethiopia
5,583 constant 2022 US$
in 2024
Jordan
5,124 constant 2022 US$
in 2024
Ethiopia rank
7th
Jordan rank
8th
Average cost of multi drug-resistant tuberculosis treatment over time
- Ethiopia
- Jordan
How they compare
Ethiopia currently reports 5,583 constant 2022 US$ against 5,124 constant 2022 US$ in Jordan, a difference of 459 constant 2022 US$.
That makes Ethiopia's figure about 1.1 times Jordan's.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Ethiopia ahead.
Ethiopia ranks 7th and Jordan ranks 8th of 92 countries.
Across the 2 decades both report, Ethiopia averaged higher in 1 and Jordan in 1.
Head to head by decade
| Decade | Ethiopia | Jordan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,815 constant 2022 US$ | 5,875 constant 2022 US$ | 2,060 constant 2022 US$ | Jordan |
| 2020s | 5,661 constant 2022 US$ | 3,905 constant 2022 US$ | 1,756 constant 2022 US$ | Ethiopia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Ethiopia or Jordan?
- Ethiopia, at 5,583 constant 2022 US$ against 5,124 constant 2022 US$ in Jordan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Ethiopia and Jordan?
- 459 constant 2022 US$, with Ethiopia ahead.
- How many years of comparable data are there for Ethiopia and Jordan?
- 7 years are reported by both, from 2017 to 2024.
- How do Ethiopia and Jordan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Ethiopia ranks 7th and Jordan ranks 8th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.